Isn't this just because Doxorubicin is more effect on its own for solid cancer?
I spoke about this in fair detail when it was announced.
From memory, the half life for decitabine is quite short, which may make the combination impractical in the clinic. I believe Inqovi increased the half life marginally, so that might be the best option. Pairing with doxorubicin is a significantly better market to target because it has an established patient base, known efficacy and problems, and Bisantrene serves as the add on to improve the efficacy and solve the problems. Decitabine combination would have to be proven to actually work in humans with solid cancers and then steal patients away from standards of care. While it might seem shiny, there is significantly more risk.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)